Although FulvicForce does not make any medical claims, there’s a body of research and scientific papers (refer to a selected list of papers at the end of this page) indicating that fulvic acid offers a significant spectrum of benefits for people afflicted with diabetes. These benefits are summarised below.

Global presence of diabetes mellitus is now epidemic and, according to the British Diabetic Association Journal, Diabetic Medicine, its prevalence worldwide is expected to double in the next 12 years.

Global presence of diabetes mellitus is now epidemic and, according to the British Diabetic Association Journal, Diabetic Medicine, its prevalence worldwide is expected to double in the next 12 years.

Research and clinical studies on animals and humans demonstrate repeatedly that fulvic acid offers a number of preventative and curative properties to help in attenuating the development and progression of diabetes mellitus. In particular fulvic acid:

  • produces significant reduction in blood glucose levels, simultaneously causing the reduction in total cholesterol level and triglyceride level
  • increases oral glucose tolerance
  • improves the lipid metabolism of diabetes and produces beneficial effects on the lipid profile
  • prevents and combats free radical damage to pancreatic islet B cells, which is the widely accepted cause for diabetes mellitus

FulvicForce is South Africa’s one and only fulvic acid product extracted from coal according to a patented process. FulvicForce product is literally an organic extract from plants, which lived hundreds of millions years ago, thus carrying their mineral, nutritional and remedial value, concentrated through a slow natural refinement process of transforming ancient plant matter into coal.


  • Activity of shilajit on alloxan-induced hyperglycaemia in rats, Bhattacharya S. K., Fitoterapia, 1995, vol. 66, no4, pp. 328-332
  • Shilajit attenuates streptozotocin induced diabetes mellitus and decrease in pancreatic islet superoxide dismutase activity in rats, Salil K. Bhattacharya, Phytotherapy Research, Volume 9, Issue 1, February 1995, Pages 41–44
  • Shilajit-induced potentiation of the hypoglycaemic action of insulin and inhibition of streptozotocin induced diabetes in rat, N. Kanikkannan, P. Ramarao, S. Ghosal, Phytotherapy Research, Volume 9, Issue 7, November 1995, Pages 478–481
  • Application of Fulvic Acid and its derivatives in the fields of agriculture and medicine, Yuan, Shenyuan; et al, Diabet Med 1997; 14:S7-S85. Diabetes Care 1998, 21:296-309.
  • Effect of shilajit on blood glucose and lipid profile in alloxan-induced diabetic rats, N. A. Trivedi, B. Mazumdar, J. D. Bhatt, K. G. Hemavathi, Indian J Pharmacol, December 2004, Vol 36, Issue 6, 373-376
  • MEDICAL ASPECTS AND APPLICATIONS OF HUMIC SUBSTANCES, Renate Klocking, Bjorn Helbig, Biopolymers for Medical and Pharmaceutical Applications,, 2005, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, ISBN: 3-527-31154-8
  • The Research Survey of Traditional Chinese Medicine Used in Therapeutic Treatments of Diabetes Mellitus, Jiang Fei and Qian Shihui, Chinese Wild Plant Resources, May 2009
  • Effects of adjunct therapy of a proprietary herbo-chromium supplement in type 2 diabetes: A randomized clinical trial, Tuhin Biswas K., Gobinda Polley, Srikanta Pandit, Debnath K. Pratip, Mondal Somoresh, Auddy Biswajit, Dipankar Banerjee, Sauryya Bhattacharyya, Pal Debasish, Shibnath Ghosal, Int J Diab Ctries, Juy-September 2010, Volume 30, Issue 3
  • Hypoglycemic Effect of Fulvic Acid and Sodium Fulvate on Diabetic Mice, HE Jing,BI Yan-yan,LI Bao-cai, LI Yue-mei, CUI Jia-li,MEI Zhan-qing, Journal of Kunming University of Science and Technology (Natural Science Edition), May 2011
  • ANTIDIABETIC HERBAL DRUGS A REVIEW, Pritesh Patel, Pinal Harde, Jagath Pillai, Nilesh Darji and Bhagirath Patel, Pharmacophore 2012, Vol. 3 (1), 18-29
  • Comparative Antidiabetic Profile of Ayurvedic Herbo-mineral Formulation and its Constituents on Normal and Streptozotocin-induced Diabetic Rats, Akansha Mishra, Rohit Srivastava, Arvind K. Srivastava, Int. J. Pharm. Sci. Rev. Res., 22(2), Sep – Oct 2013; nᵒ 46, 252-263